Innocan Pharma's Exciting Research Breakthrough
Israel-based Innocan Pharma Corporation (CSE: INNPD) has recently shared exciting developments regarding its innovative liposomal-Cannabidiol (LPT-CBD) platform. This pharmaceutical company is dedicated to advancing the fields of drug development and biotechnology, and their latest study showcases impressive results from testing in Göttingen minipigs. This animal model is widely acknowledged for its relevance in toxicology and pharmacology assessments.
Research Highlights from the LPT-CBD Study
The company has reported on a groundbreaking research article titled Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen Minipigs and Rabbits, published in the respected Precision Nanomedicine journal. This research marks an important milestone for Innocan in their quest to explore LPT-CBD's potential impact on human health.
Key findings from the study reveal that minipigs displayed prolonged plasma levels of Cannabidiol (CBD) for an impressive 28 days following a single subcutaneous injection of LPT-CBD. This aspect of the research indicates that the metabolic response observed in minipigs is closely aligned with that experienced by humans, opening the door for exciting possibilities in translating these findings into human applications.
Detailed Findings and Safety Profile
The study involved administering various ascending doses of LPT-CBD to three rabbits and three Göttingen minipigs. Evaluations for pharmacokinetics and initial safety parameters took place over a span of 10 days for rabbits and 28 days for the minipigs. Highlights from the study include:
- Lasting CBD concentration detected in plasma for as long as 28 days in minipigs.
- Younger minipigs showed high levels of the CBD metabolite 7-COOH-CBD, similar to human metabolic activity.
- No adverse effects were reported in minipigs during the study, showcasing a promising tolerability profile.
- Minimal local reactions were noted after injections, with only slight histopathological findings.
Göttingen minipigs serve as a crucial non-rodent species for regulatory evaluation of drug safety. Their unique anatomical and physiological characteristics make them ideal models for studying pharmacokinetics, toxicity, and drug potential.
Statements from Company Leadership
“This research affirms the reliable release of CBD following just one subcutaneous injection of LPT-CBD,” remarked Professor Chezy Barenholz, Head of the Advisory Board. His insights reinforce the study's impact and underline Innocan's commitment to excellence in pharmaceutical research.
Dr. Eyal Kalo, Vice President of Research and Development, expressed satisfaction with the alignment achieved with regulatory authorities regarding their future plans for clinical trials. He noted that this preliminary research lays a crucial groundwork for ongoing investigations concerning the pharmacokinetics and safety of LPT-CBD within regulatory frameworks.
About Innocan Pharma
Innocan is recognized as a trailblazer within both pharmaceutical and wellness industries. The firm has developed an innovative drug delivery mechanism utilizing CBD-loaded liposomes, designed for precise dosing and controlled release, particularly aimed at non-opioid pain management strategies. Furthermore, Innocan also curates a portfolio of high-quality self-care and beauty products that promote wellness and healthy living, collaborating through their 60%-owned subsidiary, BI Sky Global Ltd., to enhance online sales channels.
Frequently Asked Questions
What is LPT-CBD?
LPT-CBD is Innocan Pharma's liposomal-Cannabidiol drug delivery system designed for effective and prolonged CBD release.
What were the results of the study on Göttingen minipigs?
The study found prolonged plasma CBD levels for 28 days and no adverse effects post-injection, indicating good safety and tolerability.
How do Göttingen minipigs contribute to drug safety assessment?
These minipigs are recognized for their physiological similarities to humans, making them valuable models for drug testing.
What are Innocan's future plans following this study?
The company aims to further investigate LPT-CBD under FDA guidelines and prepare for potential human trials.
How can I learn more about Innocan Pharma?
For more information, you can visit Innocan Pharma's official website to explore their innovations and products.
